By reducing variability in place of ad-hoc patient samples it enables increased reliability and faster development of new therapeutics. Congenital dyserthropoietic anaemia IV (CDA IV) is a rare red ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback